Toseina is a prescription-only oral solution (cough syrup) manufactured primarily in Spain, containing 2 mg of codeine phosphate hemihydrate per milliliter of liquid. It belongs to the pharmacological class of opioid antitussives (cough suppressants) and central nervous system (CNS) depressants.because it is a codeine-based opioid, Toseina carries a high potential for misuse, dependency, and regulatory restriction.
Disclaimer: This information is for general knowledge and should not be taken as medical advice. Consult with a healthcare provider before using this or any other medication.
Approved Medical Use
The official therapeutic indication for Toseina is the short-term, symptomatic treatment of unproductive, dry coughs (coughs that do not produce mucus or phlegm).
• Mechanism: The active codeine works by acting directly on the medullary cough center in the brain, lowering neurological signals to suppress the physical urge to cough • Pediatric Ban: Toseina is strictly contraindicated in children under 12 years of age due to the unpredictable risk of life-threatening respiratory depression.
• Adolescent Guardrails: It is not recommended for adolescents between 12 and 18 years old who undergo surgery to remove their tonsils or adenoids (tonsillectomy), or those with compromised respiratory function.
• Ultra-Rapid Metabolizers: Individuals who have a genetic variation causing them to be "ultra-rapid metabolizers" convert codeine into morphine incredibly fast, leading to dangerously high morphine levels in the blood, causing sudden toxic effects even at standard levels.
• Pregnancy and Breastfeeding: It is completely contraindicated during pregnancy and breastfeeding, as codeine and morphine pass freely into breast milk and can cause fatal respiratory failure in nursing infants